Navigation Links
Cephalon Provides Clinical Update on Lestaurtinib in Relapsed Acute Myelogenous Leukemia
Date:6/19/2009

FRAZER, Pa., June 19 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) today announced results from a pivotal clinical trial of lestaurtinib (CEP-701) in patients with relapsed acute myelogenous leukemia (AML) expressing FLT3 activating mutations. The study was designed to show the benefit of lestaurtinib in this patient population when given in sequence with standard induction chemotherapy compared to those treated with standard induction chemotherapy alone. An analysis of the study showed that patients who were treated with lestaurtinib showed similar rates of complete response but no increased benefit in overall survival, compared to those who received induction chemotherapy alone.

"We are disappointed that this study with lestaurtinib did not demonstrate a benefit for this patient population but we remain committed to oncology clinical research and developing innovative therapies for life-threatening diseases," said Dr. Lesley Russell, Executive Vice President and Chief Medical Officer at Cephalon.

The results of this study in relapsed AML will be submitted for presentation at a future medical meeting. The outcome of this study has no impact on the company's previously issued financial guidance for 2009.

"We made a significant financial investment in this pioneering effort to develop lestaurtinib for this molecularly targeted patient population with a poor prognosis and few treatment options," said Frank Baldino, Jr., Ph.D., Cephalon founder, chairman and CEO. "Patients with life-threatening diseases need companies like Cephalon to make that investment and take that risk if we are to improve patient outcomes and the overall cost of healthcare."

Developed by Cephalon scientists, lestaurtinib is a potent inhibitor of several tyrosine kinases including FLT3 and a Janu
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Cephalon Announces Positive Results from a Phase Three Study of NUVIGIL in Jet Lag Disorder
2. Cephalon Announces Positive Results From a Phase Two Study of NUVIGIL in Bipolar Depression
3. Cephalon Signs Option Agreement to Acquire Ception Therapeutics
4. Cephalon Receives Complete Response Letter Regarding Request for Expanded FENTORA Label for Non-Cancer Breakthrough Pain
5. Journal of Clinical Oncology Publishes Study of Cephalon Medication TREANDA Plus Rituximab in Relapsed Non-Hodgkins Lymphoma
6. Cephalon Announces Positive Results from Its Pivotal Study of TREANDA in Patients with Non-Hodgkins Lymphoma
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. Celladon Provides MYDICAR(R) Program Update of First-In-Human Trial for Advanced Heart Failure at American Society of Gene Therapy Annual Meeting
9. Encorium Group Provides Update to LOI with Respect to the Sale of its U.S. Business
10. RAPAFLO(TM) (silodosin) Provides Rapid and Sustained Benign Prostatic Hyperplasia (BPH) Symptom Relief in as Little as Three Days
11. BioCryst Provides Peramivir Update and Reports First Quarter 2009 Financial Results

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)..., WHAT:RomHoubens,aBelgianmanthoughttohavebeenin...ullyconsciousandawakeduringthattimeandwasthesubjec...eaturedinthesegmenttoillustratehowpeoplewithLocked...n. ,, WHEN:GoodMorningAmerica-- Tuesday,Novembe..., WHO:RomHoubenswasanengineeringstudentin1986wh...
(Date:11/24/2009)...4/PRNewswire/-- EisaiInc.andPfizerIncannouncedtod...ptedforreviewEisai,sNewDrugApplication(NDA)foronce...)tabletsforthetreatmentofmoderatetosevereAlzheimer...23mgofdonepezilHClinanextendedrelease,matrix-typet...eofthedrug.TheNDAisbasedonahead-to-headclinicalstu...
(Date:11/24/2009)...harmaceuticalInstitute,aleadingproviderofspecializ...ndustry,todayannouncedthelaunchofanewe-coursetitle... e-courseisthenewestadditiontothecompany,s Managed...fe-coursesdesignedtofillthecriticalneedforbasicand...sionals. ,, Thenewthreemodule HospitalMarketpla...
Breaking Medicine Technology:DynaVox EyeMax Featured in Good Morning America Segment About Man Thought To Be in Coma for 23 Years 2FDA Accepts Once Daily 23 mg Aricept(R) Extended Release NDA for Review 2FDA Accepts Once Daily 23 mg Aricept(R) Extended Release NDA for Review 3Pharmaceutical Institute Launches New Training Resource Focused on the Hospital Marketplace 2HealthYes 21 Provides Free Preventive Screening in Support of Round Rock Express 53802 1HealthYes 21 Provides Free Preventive Screening in Support of Round Rock Express 53802 2HealthYes 21 Provides Free Preventive Screening in Support of Round Rock Express 53802 3Symposium to discuss geoengineering to fight climate change at the ESA Annual Meeting 9496 1Symposium to discuss geoengineering to fight climate change at the ESA Annual Meeting 9496 2Health reform proposals could help 13 million uninsured young adults gain coverage 53798 1Health reform proposals could help 13 million uninsured young adults gain coverage 53798 2Health reform proposals could help 13 million uninsured young adults gain coverage 53798 3
...,Corporation (Nasdaq: TGEN ) today reported on th...tes of Health (NIH) Recombinant DNA Advisory,Commi...nt reported by,Targeted Genetics surrounding the d...hase I/II trial of tgAAC94 for inflammatory arthri...t time in a comprehensive,manner and showed that h...
...phagenics,Limited (ASX: POH, AIM: PSG, OTCQX: PPGN...linical studies, it plans to undertake a Phase 1 t...ding chronic pain sufferers with a,sustained-relea...mitted all necessary documents for approval of the...pendent clinical research,organization located at ...
Other Medicine Technology:Targeted Genetics Reports on Recombinant DNA Advisory Committee (RAC) Review of its Phase 1/2 Trial of tgAAC94 for Rheumatoid Arthritis 2Targeted Genetics Reports on Recombinant DNA Advisory Committee (RAC) Review of its Phase 1/2 Trial of tgAAC94 for Rheumatoid Arthritis 3Targeted Genetics Reports on Recombinant DNA Advisory Committee (RAC) Review of its Phase 1/2 Trial of tgAAC94 for Rheumatoid Arthritis 4Phosphagenics to Conduct a Phase 1 Transdermal Oxycodone Clinical Trial 2
(Date:11/24/2009)...antros,aleadinghealthcareanalyticsanddecisionsuppo...haslicensedintellectualpropertyandassociatedsoftwa...intoQuantros,suiteofsafetyandriskmanagement(SRM)pr...eSRMproductfamilywillenableautomatedsafetydataanal...thcareprovider,sintegratedadministrativedata.These...
(Date:11/24/2009)...ing firm LocumTenens.com, a leading provider of te... its agreement with VHA Inc., a national healthcar...assignments. , Alpharetta...iting firm LocumTenens.com , a leading provider ...ounce its agreement with VHA Inc., a national heal...
(Date:11/24/2009)...P,Inc.todayannouncedtheacquisitionofRetirementCapi...mpensationandbenefitplanprovidersheadquarteredinSa...,Milwaukee,Boston,ChicagoandAtlanta.RCGwasfoundedi...ivebenefitsindustry. ,, "Weareexcitedtoannounce...tpresence,"statesBillPollock,ChairmanandFounderofN...
(Date:11/24/2009)...e/--Bionorica,aninternationalcompanypioneeringclin...ilabilityofneweducationalresourcesforparentswhowan...tayingNaturallyHealthyduringtheHolidays,"thefirsti...ompany,swebsiteat www.bionoricausa.com . ,, Par...NaturalMomstipsheets,withcontentcontributedbyexper...
(Date:11/24/2009)... too loud, or contain dangerous chemicals , ...holiday shopping season begins, parents need to kn...n stores across the United States. , That,s the... report, released Tuesday by the U.S. Public Inte...s on toys that pose a choking hazard, are excessiv...
Breaking Medicine News(10 mins):Health News:Quantros Licenses Adverse Event Identification Technology from University of Michigan 2Health News:VHA Names LocumTenens.com as Preferred Physician Staffing Vendor 2Health News:NIP Acquires San Diego Executive Benefits Firm 2Health News:Bionorica Offers Expert Resources, Health Tips for 'Natural Moms' 2Health News:Dangerous Toys Still on Store Shelves, Report Finds 2Health News:Dangerous Toys Still on Store Shelves, Report Finds 3
... NCCN names Cold Spring Publishing, LLC, as the ne...e National Comprehensive Cancer Network. Cold Spri... company led by Jack Gentile, founder of PRR, Inc....y(TM). , , FORT WASHINGTON, Pa., Feb. 10 JNCCN ...
...China, Feb. 10 /PRNewswire-Asia-FirstCall/ -- Chin...r ,the Company,) (Nasdaq: CSKI ), a,leading full...-the-counter,drugs in the People,s Republic of Chi...ibution from its recent,acquisitions, the Company ...
...led 2.7 million prescriptions through AZ&Me(TM...el., Feb. 10 AstraZeneca (NYSE: AZN ) announc...s to 440,541 patients in the United States last ye...neca is committed to helping patients who are faci...
...b. 10 HMS (Nasdaq: HMSY ) today announced that ...m Neighborhood Health Providers and Optima Health,... lives to its managed care portfolio. HMS will pro...coverage not previously known for its Medicaid mem...
...ems to reduce the risk of cognitive impairment, de...s) -- Chalk up another endorsement for the so-call...s rich in fruits, vegetables, fish and olive oil, ... -- marked by forgetfulness and difficulty concent...
...Calif., Feb. 10 Firefighter and wife help others ... Veteran firefighter Bryan Russell, from the "OC,"...nnifer found the hero in her life when she met fir...e asks, "Do you know any single people?" In Jenn a...
Other Medicine News:Health News:JNCCN Names New Publishing Company 2Health News:JNCCN Names New Publishing Company 3Health News:China Sky One Medical, Inc. Reaffirms Guidance for 2008 Revenue and Net Income and Provides Business Update 2Health News:China Sky One Medical, Inc. Reaffirms Guidance for 2008 Revenue and Net Income and Provides Business Update 3Health News:AstraZeneca Helped More Than 440,000 Patients Save $612 Million on Medicines in 2008 2Health News:HMS Awarded New Contracts for Managed Care Services 2Health News:Mediterranean Diet Aids the Aging Brain: Study 2Health News:Mediterranean Diet Aids the Aging Brain: Study 3Health News:Heroes Find Love, Love Finds Heroes 2
... ARUP Laboratories is a national reference laborat...y research and development. ARUP offers an extensi...tests in clinical and anatomic pathology. Owned by...s include more than half of the nation's universit...
... ARUP Laboratories is a national reference laborat...y research and development. ARUP offers an extensi...tests in clinical and anatomic pathology. Owned by...s include more than half of the nation's universit...
... ARUP Laboratories is a national reference laborat...y research and development. ARUP offers an extensi...tests in clinical and anatomic pathology. Owned by...s include more than half of the nation's universit...
... ARUP Laboratories is a national reference laborat...y research and development. ARUP offers an extensi...tests in clinical and anatomic pathology. Owned by...s include more than half of the nation's universit...
Medicine Products: